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Abstract 
Background: High grade serous carcinoma (HGSC) whether ovarian, tubal or primary 
peritoneal, continues to be the most lethal gynecologic malignancy in the USA. 
Although combination chemotherapy and aggressive surgical resection has improved 
survival in the past decade, the majority of patients still succumb to chemoresistant 
disease recurrence. It has recently been reported that amplification of 5q31-5q35.3 is 
associated with poor prognosis in patients with high grade serous ovarian carcinoma. 
Although the amplicon contains over 50 genes, it is notable for the presence of several 
members of the fibroblast growth factor signaling axis. In particular, acidic fibroblast 
growth factor 1 (FGF1) has been demonstrated to be one of the driving genes in 
mediating the observed prognostic effect of the amplicon in ovarian cancer patients 
This study seeks to further validate the prognostic value of fibroblast growth receptor 4 
(FGFR4), another candidate gene of the FGF/FGFR axis located in the same 
amplicon. The emphasis will be delineating the role of the FGF1/FGFR4 signaling axis 
in high grade serous ovarian carcinoma, and test the feasibility of targeting the 
FGF1/FGFR4 axis therapeutically. 
Materials and Methods: Spearman and Pearson correlation studies on data generated 
from array CGH and transcriptome profiling analyses on 51 microdissected tumor 
  vi 
 
samples were used to identify genes located on chromosome 5q31-35.3 that showed 
significant correlation between DNA and mRNA copy numbers. Significant correlation 
between FGF1 and FGFR4 DNA copy numbers was further validated by quantitative 
PCR analysis on DNA isolated from 51 microdissected tumor samples.  
Immunolocalization and quantification of FGFR4 expression were performed on 
paraffin embedded tissue samples from 183 cases of high-grade serous ovarian 
carcinoma. The expression was then correlated with clinical data to assess impact on 
survival. The in vitro expression of FGF1 and FGFR4 was quantified by real-time PCR 
and western blot of six high-grade serous ovarian carcinoma cell lines and compared 
to human ovarian surface epithelial cells to identify overexpression. The effect of FGF1 
on these cell lines after serum starvation was quantified for in vitro cellular 
proliferation, migration/invasion, chemoresistance and survival utilizing a combination 
of commercially available colorimetric, fluorometric and electrical impedance assays. 
To assess FGF1:FGFR4 specific signaling effects, FGFR4 expression was then 
transiently silenced via siRNA transfection and the effects cellular proliferation and 
migration in response to FGF1 were quantified. To identify relevant cellular pathways 
involved, responsive cell lines were transduced with different transcription 
response elements using the Cignal Lenti reporter system and treated with 
FGF1 with and without transient FGFR4 knockdown.  This was followed by 
western blot confirmation for the relevant phosphoproteins. Anti-FGF1 
antibodies and FGFR trap proteins were used to inhibit FGF1 mediated 
phenotypic changes and relevant signaling in vitro. To model this effect in vivo, 
orthotopic intraperitoneal tumors were established in nude mice using serous 
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ovarian cancer cell lines that have been previously transfected with luciferase 
expressing constructs. The mice were then treated with FGFR trap protein. Tumor 
progression was then followed via bioluminescent imaging. To exclude presence of 
activating mutations, the FGFR4 gene from 43 patients was sequenced. 
Results: FGFR4 DNA and mRNA copy numbers were significantly correlated and 
FGFR4 DNA copy number was significantly correlated with that of FGF1.  Survival of 
patients with high FGFR4 expressing tumors was significantly shorter than those with 
low expression (median survival 28 vs. 55 month, p< 0.001). In a multivariate Cox 
regression model, FGFR4 expression significantly increased risk of death (H.R. 2.1, 
p<0.001). FGFR4 expression was significantly higher in all cell lines tested compared 
to HOSE; the OVCA432 cell line, in particular, had very high expression suggesting 
amplification. FGF1 was also particularly overexpressed in OVCA432. FGF1 
significantly increased cell survival after serum deprivation in all cell lines. Transient 
knockdown of FGFR4 caused significant reduction in cell migration and proliferation in 
vitro and significantly decreased the proliferative effects of FGF1 in vitro. FGFR1, 
FGFR4 traps and anti-FGF1 antibodies did not show activity in vitro. OVCA432 
transfected with the Cignal Lenti reporter system revealed significant activation of 
MAPK, NFkB and WNT pathways; western blotting confirmed these results. Reverse 
phase protein array (RPPA) analysis also showed activation of MAPK, AKT, WNT 
pathways and down-regulation of E-Cadherin. FGFR1 trap protein significantly 
reduced tumor growth in vivo in an orthotopic mouse model.    
Conclusions:  Overexpression and amplification of several members of the FGF/FGFR 
signaling axis present on the amplicon 5q31-35.3 is a negative prognostic indicator in 
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high grade serous ovarian carcinoma and may drive poor survival associated with that 
amplicon. Activation of the FGF signaling pathway leads to downstream activation of 
MAPK, AKT, WNT and NFkB pathways leading to a more aggressive cancer 
phenotype with increased tumor growth, evasion of serum-starved apoptosis, and 
increased migration and invasion. Inhibition of the FGF pathway in vivo via FGFR trap 
protein leads to significantly decreased tumor growth in an orthotopic mouse model.
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Introduction 
High grade serous carcinoma (HGSC) is the most common malignant carcinoma 
arising from the ovary and fallopian tube, and second most common gynecologic 
cancer after corpus carcinoma in the USA [1]. It also remains the most fatal 
gynecologic malignancy as most patients succumb to recurrence after successful 
primary treatment with combined debulking surgery and chemotherapy  [2].  
Ovarian cancers are thought to arise from the tissues making up the female gonads. 
Ovarian neoplasia is broadly subdivided into epithelial tumors originating from the 
cuboidal epithelial cell covering the surface of the ovary, sex-cord stromal tumors 
originating from connective tissue elements, and germ-line tumors originating from 
remnant embryonic tissue. Epithelial tumors are by far the most common, accounting 
for more than 90% of cases. 
Epithelial ovarian cancers are also subdivided into several histological subtypes as 
they resemble other endodermal tissues rather than the postulated tissue of origin. 
Mucinous tumors resemble appendiceal tumors; they predominantly produce mucin 
with abundant goblet-like cells dominating their architecture. Endometrioid tumors 
resemble endometrial carcinomas with endometrial gland-like architecture. Clear cell 
tumors are characterized by perinuclear clearing and production of glycogen. 
Transitional cell tumors are rare and resemble urothelial epithelium (table I1). 
Serous tumors are the most common type of epithelial ovarian tumors. They 
histologically resemble the ciliated epithelium of the fallopian tube. Serous tumors 
arising from the fallopian tube itself and the mesothelial covering of the female 
peritoneum are histologically indistinguishable from serous ovarian tumors. Recently, 
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the origin of serous ovarian tumors has been challenged. Discovery of fallopian 
intraepithelial neoplasia and evidence from profiling studies now point towards 
fallopian tube epithelium as the tissue of origin [3]. 
In addition to histological subtypes, epithelial ovarian tumors are further divided into 
borderline tumors, low grade, and high grade carcinomas. Borderline tumors are 
characterized by lack of invasion, well-differentiated histology, and relatively indolent 
course. Low grade tumors histologically resemble borderline tumors but are invasive 
and are associated with a poorer prognosis. High grade tumors are the most common 
subtype. They are the least differentiated of the subtypes and clinically most 
aggressive. HGSCs are the most common of all high grade ovarian tumors accounting 
for 60-80% of the cases [4].  
Genome profiling of epithelial tumors suggests two distinct pathways for their 
pathogenesis (Figure I2). Borderline tumors and low grade tumors both share a high 
incidence of KRAS and BRAF mutations, and lack p53 mutations. High grade tumors, 
on the other hand, are characterized by p53 mutations and lack of KRAS and BRAF 
aberrations. It has been suggested that borderline and low grade tumors present a 
continuum of neoplastic development that starts with activating mutations in the MAPK 
pathway within ovarian inclusion cysts as the precursor lesions. High grade serous 
tumors on the other hand are thought to derive from fallopian intraepithelial neoplasia 
characterized by p53 loss of function [3]. 
The cornerstone of treatment of HGSC is primary surgical cytoreductive surgery with 
the aim of reducing tumor burden to microscopic disease [5]. This is usually followed 
by adjuvant combined treatment with a platinum and taxane containing chemotherapy,  
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Epithelial Ovarian Tumor Type Representative section 
Serous  
(resembles Fallopian tube) 
 
Mucinous  
(resembles GI goblet glands) 
 
Endometrioid  
(resembles endometrial glands) 
 
Clear cell  
(resembles GI endoderm) 
 
Transitional 
(resembles bladder urothelium) 
 
Table I1 .The histologic sub types of epithelial ovarian carcinomas.  
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which affords 80% of patients an initial complete response and a disease free period 
ranging between twelve and twenty four months [6]. Most patients present in late stage 
advance disease (stage III-IV).  Abdominal and pelvic recurrence rates are high and 
response to further chemotherapy is limited [7].  Attempts at introducing biologic 
therapeutic agents to improve outcome in this disease are ongoing [8]; however thus 
far, only the anti-VEGF antibody, bevacizumab, has been reported to have clinical 
activity in a phase III clinical trials [9].  
Our group has recently reported that the amplicon 5q31-35.3 is a negative prognostic 
indicator in HGSC and that overexpression of fibroblast growth factor 1 (FGF1) is 
implicated in reducing survival [10]. It was notable that several members of the 
fibroblast growth factor family are also present on 5q31-35.3, including fibroblast 
growth factor 18 (FGF18), and the fibroblast growth factor receptor 4 (FGFR4) [11], 
which may also be involved in ovarian cancer progression.  
Fibroblast growth factors (FGFs) are a family of small signaling proteins with a wide 
range of biologic effects. To date, 18 members of the FGF family have been described 
in mammals.  All share a core 120 amino acid region and differ in structure at their 
carboxy & amino terminals [12]. Receptor tyrosine kinases (RTKs) are the main target 
by which FGF ligands induce signal transduction, although some direct nuclear 
signaling has been reported [13]. FGFs are expressed in a variety of tissues and have 
been implicated in angiogenesis [14], embryonic  development/differentiation [15] and 
tumorigenesis [16]. FGFs have been shown to signal through autocrine, endocrine and 
paracrine pathways [17].  FGFs involvement in cancer biology have been well 
documented [18], with different members playing diverse roles related to the cancer 
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phenotype including tumor proliferation [19], survival [20], migration/invasion [21], EMT 
[22] and angiogenesis [23].    
 
Figure I1. Distribution of stage and prognosis in ovarian epithelial carcinoma. 
 
 
Figure I2. Illustration of the different pathways potentially leading to low versus high grade ovarian 
carcinoma.  Abbreviations: APST, atypical proliferative serous tumor; CIN, chromosomal instability; LOH, loss of 
heterozygosity; MPSC, micropapillary serous carcinoma. Figure modified from reference [24] with permission. 
Stage   Description Incidence    Survival
I Confined to ovaries 20% 90%
II Confined to pelvis 5% 65%
III Spread IP or nodes 58% 45%
IV Distant metastases 17% <5%
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FGF signaling is mediated through 4 transmembrane RTKs that are a product of 4 
highly conserved genes, FGFR1 through FGFR4 [12] . Through alternative splicing, 14 
variants of FGFRs have been described across the 4 FGFR classes, with only FGFR4 
lacking multiple isoforms [25]. The prototypical structure of FGFR consists of 3 
extracellular immunoglobulin-like domains (IgI-IgIII) which impart ligand specificity at 
the amino terminus,  followed by a transmembrane domain and a highly conserved 
split tyrosine kinase domain at the carboxy end [26]. 
As with many RTKs, activation of the FGF signaling axis requires FGF ligand binding 
to and subsequent dimerization and autophosphorylation of FGFR [27]. This 
interaction requires presence of heparin sulfate glycosaminoglycans which acts to 
increase binding affinity, stabilize the ligand/ receptor dimer, and increase half life [28].  
Once binding of the FGF-heparin complex occurs, receptors dimerize with subsequent 
autophosphorylation of the intracellular domain tyrosine residues, paving the way for 
activation of several intracellular signaling pathways [29].  
FGFR downstream signaling leads to activation of several second messenger 
pathways with a variety of outcomes depending on ligand, receptor, cell and tissue 
type, and cross talk with other pathways [27]. The docking protein, FGFR substrate 2 
(FRS2), plays a critical role in activation of MAPK/ERK and PI3K/AKT pathways 
downstream of FGFR. FRS2 is bound to the juxtamembrane portion of FGFR; once 
FGFR is activated and autophosphorylated, FRS2 is recruited and also undergoes 
phosphorylation by the activated receptor. The phosphorylated FRS2 recruits the 
adaptor proteins Sons of Sevenless (SOS) and growth factor receptor-bound 2 
(GRB2), which subsequently activates RAS, downstream RAF, and eventually 
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MAPK/ERK pathway [26, 30]. Through GRB2 associated protein 1, the FGFR-FRS2-
GRB2 complex can also bind and activate PI3K with downstream activation of Akt [31]. 
The phosphorylated carboxy-terminus of FGFR can also bind the SH2 domain of 
phospholipase C with subsequent activation of PKC pathway [32]. STAT pathway 
activation has been described with FGFR3 but the mechanism remains unclear [33]. 
Termination of FGFR signaling involves feedback inhibition by several pathways. Non-
specific attenuation of FGFR signaling is mediated through RTK inhibitor pathways. 
These include members of the Sprouty (Spry) family, which work by inhibition of ERK 
activation through sequestration of GRB2 [34]. MKP3 (MAPK phosphatase 3) is 
another inhibitor of RTK signaling that also acts by dephosphorylating ERK [35]. A 
single pass transmembrane protein encoded by the SEF gene has been identified as 
specific inhibitor of  FGFR1, it is thought to prevent tyrosine kinase activation by biding 
to the receptor, but the exact mechanism is unknown [36, 37]. 
Germ line mutation in the FGF pathway is involved in several skeletal dysplasias. 
Activating mutations on the FGFR genes are reported in craniosynostosis (of 
premature fusion of 1 or more cranial sutures) and thanatophoric dysplasia (extremely 
short limbs and folds of extra skin on the arms and legs) [38]. No predisposition or 
familial cancer syndromes have been reported with the FGF pathway. However, driver 
mutilations with downstream activation of the pathway are known to be driver mutation 
in certain types of multiple myeloma where fusion proteins produce continuous 
activation of the FGFR kinase domain [39]. Aberrations in the expression and 
mutations of FGFs and FGFRs in the solid tumors, to which HGSC belongs, have 
been reported to play an important role in their pathogenesis (Table l1).  
  8 
 
 
Figure I4. FGF and Heparin glycosaminoglycan complex(HLGAG) bound to FGFR causing receptor dimerization 
and autophosphorylation of the intracellular domain, adapted with permission from reference  [25]. 
 
Figure I3.Structure of the 4 FGFR receptors and their different splice variants, adapted with  permission from 
reference [25] 
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Figure I5. Downstream second messenger pathways activated by FGF signaling and associated molecules, 
adapted from reference with permission [40]. 
Activating mutations in the kinase and intermembrane domains are reported in 
approximately 50% of non-invasive bladder carcinomas [41].  Mutations of FGFR2, 
which are identical to the activating germline mutations found in craniosynostosis 
syndromes, have been described in 12% of endometrial carcinomas [42]. In breast 
carcinomas, the 8p11-p12 amplicon, which contains FGFR1, is observed in about 10–
15% breast cancer patients [43]. Amplification and overexpression of FGFR2 is 
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observed in about 4–12% breast tumors whilst FGFR4 protein is overexpressed in 
around 30% patients [44, 45]. 
Gene Cancer type  References 
FGFR1 
Amplification Breast cancer , ovarian cancer , bladder cancer and rhabdomyosarcoma   [46-50] 
Mutation Melanoma  [51] 
FGFR2 
Amplification Gastric cancer  and breast cancer  [52, 53]  
Mutation Endometrial cancer  and gastric cancer  [54, 55] 
Germline SNP Second intron SNP: increased incidence of breast cancer [56, 57] 
FGFR3 
Amplification Bladder , salivary adenoid cystic cancers [58, 59] 
Mutation Bladder cancer , cervical cancer , prostate  and spermatocytic seminoma  [41, 60-64] 
FGFR4 
Mutation Rhabdomyosarcoma  [65] 
Germline SNP Coding SNP: poor prognosis breast, colon and lung adenocarcinoma [66, 67] 
FGF1 
Amplification Ovarian  [10] 
Table I2. FGF/FGFR axis aberrations reported for various solid tumors. 
Activating mutations in the kinase and intermembrane domains are reported in 
approximately 50% of non-invasive bladder carcinomas [41].  Mutations of FGFR2, 
which are identical to the activating germline mutations found in craniosynostosis 
syndromes, have been described in 12% of endometrial carcinomas [42]. In breast 
carcinomas, the 8p11-p12 amplicon, which contains FGFR1, is observed in about 10–
15% breast cancer patients [43]. Amplification and overexpression of FGFR2 is 
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observed in about 4–12% breast tumors whilst FGFR4 protein is overexpressed in 
around 30% patients [44, 45]. FGFR2 amplification has been found in up to 10% of 
primary gastric cancers[55], activating mutations have also been found in FGFR2 in 
primary gastric cancers [68]. The SNP Gly388Arg has been reported to be a poor 
prognostic indicator in breast, lung, and colon carcinomas [67]. 
Since FGFR inhibition can reduce proliferation and induce cell death in a variety of in 
vitro and in vivo tumor models, inhibitors of FGFR or FGFR-dependent downstream 
signaling pathways may represent useful therapeutic agents. FGFR inhibition can be 
achieved by several approaches and both small molecule tyrosine kinase inhibitors 
directed against FGFR activity, and FGFR-antagonistic antibodies and trap protein 
have been described[40]. 
In undertaking this investigation, we aim to build on evidence that the amplification of 
FGF pathway related genes on segment 5q31-35.3 negatively impacts survival in 
HGSC, and to explore possible avenues to intervene therapeutically to improve 
outcome in those patients. 
   
  12 
 
Hypothesis and Specific Aims 
We hypothesize that fibroblast growth factor pathway activation is one of the main 
factors in conferring poor prognosis associated with amplification of 5q31-35.3 in high- 
grade serous carcinoma. The amplification and overexpression of FGF1 ligand by 
such tumors stimulate ovarian cancer growth and survival 1) directly through autocrine 
signaling via several second messenger pathways or 2) indirectly through stimulating 
angiogenesis in a paracrine manner as previously reported. In addition, we 
hypothesize that FGFR4 is another driving gene located in the same amplicon where 
FGF1 is located.  Binding of FGFR4 ligands, including FGF1 activates the downstream 
signaling pathways, which promote ovarian cancer growth and lead to poorer patient 
survival. The hypothesized overexpression of FGF ligands and the FGFR4 receptor in 
HGSC suggest that use of biologic agents targeted to that pathway may be of 
therapeutic benefit. 
 
Figure H1. Illustration of central hypothesis. 
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The specific aims are as follows: 
1. To quantify the expression of FGFR4 in HGSC, correlate its expression to that of 
FGF1, and determine its impact on survival. 
2. To identify the mechanisms by which FGF1/FGFR4 overexpression and activation 
impact HGSC cell behavior. 
3. To identify signaling pathways in HGSC related to the FGF1/FGFR4 axis. 
4. To target the FGF1/FGFR4 axis in HGSC with suitable biologic agents to 
determine feasibility of therapeutic intervention.  
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Methods  
Validation of FGFR4/FGF1 amplification in tumor samples  
Based on previously reported CGH data [10], validation of gene copy number on 
segment 5q31-35.3 was done by quantitative polymerase chain reaction (qRT-PCR) to 
assess relative copy number of the genes of interest. Sixty-three DNA samples were 
extracted as previously described for CGH analysis [10], and amplified by GenomiPhi 
whole genome amplification system (Amersham, Piscataway, NJ) according to the 
manufacturer’s instructions. qRT-PCR was then performed using primers specific for 
each gene using SYBR green as per manufacturer’s instructions (Qiagen Sciences 
Inc, Germantown, MD). DNA content was normalized to that of Line-1, a repetitive 
element for which copy numbers per haploid genome are similar among all normal and 
neoplastic cells.  Relative DNA copy number was determined by normalizing to that of 
normal human ovarian surface epithelial cells. Correlations between DNA copy 
number fold change and survival data were performed using Cox regression and 
Kaplan-Meier analysis. 
Patient samples  
Paraffin sections from 183 late stage high grade serous ovarian carcinoma cases were 
obtained from the pathology repository at the University of Texas M.D. Anderson 
Cancer Center under the approval of the Institution Review Board (IRB).  Clinical/ 
pathologic data regarding age, stage, histology, overall survival, and extent of residual 
disease after surgery was available for these sections. 
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Immunolocalization of FGFR4  
Tumor sections underwent deparaffinization by incubation in xylene for 5 minutes and 
then rehydration in decreasing concentrations of alcohol in water.  Antigen retrieval 
was then performed by heating slides to 95oC for 10 minutes in citric acid buffer (pH 
6.0). The sections then underwent immunohistochemistry staining utilizing the 
Labvision 360 Automated Stainer (Labvision Corp, Fremont, CA). A commercially 
available FGFR4 antibody was used to specifically bind FGFR4 in the fixed tissue (sc-
124 Santacruz biotech, Santa Cruz, CA). Parameters for the IHC cycle were as 
follows: 
Step Reagent (lab vision Corp, Fremont CA) Incubation time  
Endogenous peroxidase block Hydrogen peroxide block solution  15 minutes 
Protein background block Ultra V block solution 5 minutes 
Primary antibody incubation SC-124 , 1:50 dilution 90 minutes 
Secondary conjugated  polymer  Ultravision LP HRP polymer 15 minutes 
Chromogen application and development DAB Plus substrate 5 minute 
Hematoxylin  counter stain Mayer Hematoxylin solution 1 minute 
 
Digital photomicrographs of representative areas were taken at 20x magnification. 
Quantitative FGFR4 stain intensity and localization measurements were obtained by 
using ImagePro Plus software version 5.1, Figure 1M (Media Cybernetics Inc., 
Bethesda MD).  
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The resulting FGFR4 stain intensity score was used to divide the patients into low and 
high FGFR4 expression groups using the median as a cutoff point. Survival analysis 
utilizing both the Kaplan-Meier modeling (with log-rank significance testing) and Cox 
proportional hazard model were performed to determine effect on overall survival and 
risk of death. 
 
 
Figure M1. Computer assisted quantification of FGFR4 staining intensity in high-grade ovarian serous carcinoma. 
Representative images of FGFR4 IHC signal with corresponding measurement and heat map generated by software algorithm 
in (A) patient with overall survival of 10 months and (B) patient with overall survival of 90 months.  
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Cell lines and culture conditions 
The derivation and source of the human epithelial ovarian cancer cell lines A2780, 
SKOV3ip,OVCAR-3,OV5,OVCA432 ,OVCA433 have been described previously [69-
73].  All cell lines were maintained and propagated in RPMI-1640 medium 
supplemented with 10% fetal bovine serum (FBS) and 0.1% gentamicin sulfate 
(Mediatech Inc., Manassas, VA).  
Generation of OVCA432 luciferase reporter cell lines was performed by transducing 
the parental cell line with lentiviral particles containing expression plasmids encoding 
for transcription response elements for MAPK, PI3K, WNT, NFKB, NOTCH, JAK/STAT 
pathways linked to a luciferase expression system (Cignal Lenti, SA Bioscience Corp, 
Frederick, MD) according to the manufacturer’s instructions.  
Generation of the luciferase expressing cell line 432luc was done via transduction with 
lentiviral particles containing a luciferase expression system under a CMV promoter 
(Genetarget, Inc, San Diego, CA) according to the manufacturer’s instructions. 
All experiments were performed using cells grown to 60-80% confluence.  All cell lines 
were routinely genotyped and tested to confirm absence of mycoplasma. Passage 
number for cell lines did not exceed 20. 
Quantification of FGFR4 & FGF1 expression in vitro 
A) Protein quantification 
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To quantify FGF1/FGFR4 protein expression in vitro for wild type cells lines and those 
after treatment or knockdown, lysates were prepared from cells in log phase growth at 
70-80% confluence.  Cells were washed with PBS, harvested by scraping, and lysed 
with modified radioimmunoprecipitation assay (RIPA) lysis buffer (20 mM Tris-HCl (pH 
7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium 
deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM 
Na3VO4, 1 µg/ml leupeptin) supplemented with 1x protease/phosphatase inhibitor 
cocktail (Thermofisher Scientific, Waltham, MA).  Cell lysate was centrifuged at 13,400 
rpm for 10 min at 4ºC. Protein concentration was determined by a Pierce 660 nm 
Protein Assay kit (Thermofisher Scientific, Waltham, MA) according to the 
manufacturer’s instructions.  A total of 30 µg of protein from whole-cell lysate was 
subjected to SDS-PAGE on a 10% gel for 2 h at a constant 90 volts, then  transferred 
to a nitrocellulose membrane utilizing semi-dry transfer method (Bio-Rad Labs, 
Hercules, CA). The membrane was then blocked with 3% bovine serum albumin 
solution for 1 hr at room temperature and probed with commercially available primary 
antibodies (Anti-FGFR4:MAB6852, dilution 1:500, Anti-FGF1:AF232, dilution 1:1000, 
both from R&D Biosystems,  Minneapolis, MN, and  Anti-beta-actin, A1978, dilution 
1:10,000, Sigma Aldrich, St Louis, MO) at 4ºC overnight. The membranes were rinsed 
three times for 10 minutes each in tris-buffered saline (concentration of TBS?) with 
0.1% Tween twenty. Incubation for the secondary antibody was done for one hour at 
room temperature. The secondary antibodies used were IR-680LT goat anti-mouse, 
IR-800CW donkey anti-goat and IR-800CW goat anti-rat (Li-Cor Biotechnology, 
Lincoln, NE). A 1:5000 dilution was used for all secondary antibodies. The membrane 
was rinsed 3 times for 10 minutes each to reduce background signal. The membranes 
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underwent infrared imaging on a Li-Cor Odyssey system (Li-Cor Biotechnology, 
Lincoln, NE). Results were visualized using packaged software, which also performed 
quantitative band analysis via normalization to beta-actin. 
B) Messenger RNA quantification 
To quantify mRNA expression of genes under investigation, cells were grown to a 
density of 1x105 cells in six well plates; the media was then removed and washed with 
PBS at 4°C. RNA was then isolated by lysing and processing the cells via the Ambion 
Purelink RNA minikit (Invitrogen Corporation, Carlsbad, CA). Quality of collected RNA 
was then verified using a Nanodrop ND-1000 spectrophotometer (Thermofisher 
Scientific, Waltham, MA)-. cDNA synthesis was performed with the high capacity 
cDNA reverse transcription kit (Applied Biosystems, Carlsbad, CA). Quantitative RT-
PCR (qRT-PCR):  Quantitative RT-PCR was performed by TaqMan approach using 
the CFX96 Quantitative Real-Time PCR system (Bio-Rad Labs, Hercules, CA). 
FGFR4 expression levels were determined by TaqMan assay (Hs00242558-m1) while 
a Cyclophilin TaqMan probe (4326316E) was used as an endogenous control. 
TaqMan assays were performed according to the manufacturer’s suggested protocol 
utilizing a universal PCR master mix (Applied Biosystems, Carlsbad, CA). Packaged 
software from the CFX96 system was used to analyze the data.  
C) Quantification of FGF1 in conditioned medium 
To assess the level of FGF1 production by HGSC in vitro, cells were grown to 80% 
confluence at which point the medium was changed to serum free Opti-MEM 
(Invitrogen Corporation, Carlsbad, CA) and incubated for 48 h. The media was 
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subsequently collected and concentrated by filter centrifugation, after which ELISA for 
FGF1 was performed via quantakine FGF1 kit (R&D Biosystems, Minneapolis, MN).  
FGFR4 gene silencing via siRNA Transfection 
Two commercially available validated siRNAs targeted at FGFR4 and a non-target 
scramble sequence siRNA as a control were used to perform transient knockdown of 
the receptor in the cell lines under investigation (Qiagen Sciences Inc, Germantown, 
MD). Information regarding these siRNAs is given in table M1. Screening for 
successful knockdown was performed at the protein level and mRNA level for the cell 
lines in question utilizing western blot and qRT-PCR protocol described earlier (figure 
M2 & M3). Transfection was carried out according to the recommended cell densities 
and transfection reagent concentrations as suggested for reverse transcription with the 
Lipofectamine RNAi MAX (Invitrogen Corporation, Carlsbad, CA) transfection reagent. 
The concentration of siRNA used was 10nM final concentration for all siRNA duplexes 
and experiments.  
siRNA  ID 
(target gene) Target sequence Sequence 
AllStars Neg. Control siRNA 
(No target scramble 
sequence) 
CAGGGTATCGACGATTACAAA 
Sense 
GGGUAUCGACGAUUACAAAUU 
Anti sense 
UUUGUAAUCGUCGAUACCCUG
Hs_FGFR4_5 
(FGFR4) CCGCCTGACCTTCGGACCCTA 
Sense 
GCCUGACCUUCGGACCCUATT 
Anti sense 
UAGGGUCCGAAGGUCAGGCGG
Hs_FGFR4_6 
(FGFR4) CAGGCTCTTCCGGCMGTCM 
Sense 
GGCUCUUCCGGCAAGUCAATT 
Anti Sense 
UUGACUUGCCGGAAGAGCCTG
 
Table M1. siRNA oligonucleotides used in transfection experiments targeting transient knock down of FGFR4 in 
HGSC cell lines.  
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Assessment of cellular proliferation/migration   
A). Endpoint assays  
Proliferation was assessed utilizing the WST-1 colorimetric assay (Roche Applied 
Bioscience, Indianapolis, IN). Cell were plated at a density of 5,000 cells per 96 well 
and allowed to attach for 24 h in serum free Opti-MEM.  If siRNA transfection 
                                   No siRNA           Hs_FGFR4_5           Hs_FGFR4_6            Non target siRNA  
 
FGFR4 
 
 
actin 
 
Figure M2. Knock down of FGFR4 in OVCA432 after 72 h of transfection at 10 nm final concentration with different 
oligonucleotides. 
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Figure M3. Knock down of FGFR4 in HGSC at the mRNA level as measured by real time quantitative PCR after 72 
h of transfection at a final concentration of 10 nm. 
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was needed, a reverse transfection was carried at this time. After the 24 h period, 
media was then changed with media containing 2% FBS and any planned 
recombinant FGF1 treatment (R&D Biosystems, Minneapolis, MN). The cells were 
incubated for 3 days after which media was removed and WST-1 reagent diluted in 
serum free media according to the manufacturer’s instruction was added and 
incubated for 2 h. The assay was then quantified by a spectrophotometric plate reader.  
All data were normalized to respective control arms.   
Migration of HGSC cell lines was assessed with the ORIS migration assay kit 
(Platypus Technologies, Madison, WI). Cells were plated at density of 30,000 per well 
in serum free Opti-MEM into the 96 well plates provided with the assay, with the 
stoppers in place covering the central migration zone according to manufacturer’s 
instruction. If a siRNA transfection was needed, a reverse transfection was carried at 
this time. Cells were left to attach for 24 h after which media containing 2% FBS and 
any planned recombinant FGF1 treatment was added. The stoppers were left in for a 
further 12 h and then removed to allow cell migration into the central zone for 12 h. 
Cells were then stained with Calcien AM (Invitrogen Corporation, Carlsbad, CA) 
according to manufacturer’s instructions. Migration was assessed by measuring 
fluorescence in the central migration zone by a plate reader according to the protocol 
provided with the ORIS assay.  Photomicrographs were also taken with a fluorescent 
microscope.  
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B. Real time assays  
To assess cell proliferation and migration in real-time, the xCELLigence system 
(Roche Applied Bioscience, Indianapolis, IN) was used. The system measures 
electrical impedance across micro-electrodes integrated on the bottom of tissue 
culture plates. Impedance measurement provides quantitative information about the 
biological status of the cells, including cell number [74], and migration [75, 76]. Cells 
were plated at a density of 10,000/well cells for cell proliferation plates and 30,000/well 
for cell migration chambers in serum free Opti-MEM. For cell proliferation, cells were 
allowed to attach for 6-12 h and normalized to that point after which recombinant 
FGF1 was added and cell proliferation was followed on attached computer terminal 
and software.  For migration studies, media in the upper chamber was devoid of FGF1 
while media in the lower chamber contained FGF1 at various concentrations.  
 
 Figure M4. Real time measurement of effect of siRNA FGFR4 knock down.  siRNA and transfection reagent 
were mixed with cells prior to plating in wells with an electrode matrix at the bottom. The system allows realtime 
data acquisition of cell number as measured through changes in electric impendence across the well bottom. 
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Figure M5. Use of wound healing assay to assess effects of FGFR4 knock down on migration of HGSC. The 
system utilizes a stopper to create a central acellular zone into which the cells can migrate into after it has been 
removed. The system allows siRNA transfection to be done at the same time as cell seeding and also allows 
quantitative migration assessment. 
 
Assessment of cellular signaling induced by FGF1 
Cignal Lenti luciferase assay 
OVCA432 cell line transected with different reporter response elements from the 
Cignal Lenti reporter system were plated at a density of 30000 cells/well in 96 well 
plates (in serum free media) and allowed to attach to for 24 h. The media was then 
removed. Media containing 10 ng/ml FGF1 was added and allowed to incubate for 6 
siRNA
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hours. The media was then removed and the cells were washed with PBS once. An 
assay specific cell lysis buffer was then used to lyse the cell according to the 
manufacturer’s instructions (Promega Corporation Madison, WI). The plates were then 
processed by a plate reader with luminescence measurement capability, and a built-in 
injector. The injector dispensed 50 ul of luciferin solution per well and the 
luminescence was measured as recommended by the manufacturers protocol 
(Promega corporation Madison, WI). Data were normalized to their respective control 
groups.  
 
Figure M6. Use Reporter assay to screen for FGF1 pathway activation in HGSC. To screen pathway activation 
downstream of FGF pathway we constructed reporter cell lines in OVCA432 carrying response elements linked 
luciferase. Once treated with FGF 1 if the pathway is activated induced expression of luciferase will begin, in the 
presence of luciferin luminescence will be observed which we can measure as an indicator of pathway activation  
Reverse phase protein array 
OVCA432 were grown in six well plates until 80% confluent.  Cells were then serum 
starved for 24 h. FGF1 at 10 ng/ml was then added to the experimental wells and 
incubated for 3 h. The cells were processed and the lysates were subjected to RPPA 
at the MD Anderson Core proteomics laboratory using their previously reported 
protocol [77, 78] 
Transcription response element
(Promoter sequence for specific biochemical pathway)
Reporter gene
(Firefly luciferase)
FGF1 Transcription
factor
Luciferase
Luminescence 
measurement
Reporter Cell Line Luciferase Assay
Luciferin
substrate
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Western blotting  
To confirm results of the reporter assay and RPPA, western blots of lysates from 
FGF1 treated cells versus serum starved controls were performed according to the 
protocol described earlier for FGFR4 with the substitution of different primary 
antibodies against the proteins of interest. These antibodies are given in the table 
below. 
Antibody Dilution Manufactures 
Total Erk(L34F12) 1:1000 Cell Signaling(Beverly, MA ) 
Phospho Erk(D13.14.4E) 1:1000 Cell Signaling(Beverly, MA ) 
Total Akt(40D4) 1:1000 Cell Signaling(Beverly, MA ) 
Phospho Akt(D9E) 1:1000 Cell Signaling(Beverly, MA ) 
NFKB p65 (93h1) 1:1000 Cell Signaling(Beverly, MA ) 
Phospho NFKB p65(C22B4) 1:1000 Cell Signaling(Beverly, MA ) 
 
Sequencing of FGFR4  
DNA from 43 microdissected clinical samples was isolated and amplified as described 
earlier for CGH. PCR amplification of FGFR4 exons 9-16 (intermembrane and kinase 
domain) followed by purification and sequencing was performed as previously 
published [65]. The primer sequences used are given in table M2.  
Therapeutic targeting of FGF pathway in vitro  
An OVCA432-luciferase-transfected cell line (OVCA432-Luc) was generated in our 
laboratory as described earlier. An FGFR1 Fusion trap protein currently under 
development as a biologic therapeutic, FP-1039, was obtained from Fiveprime 
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Therapeutics Inc, San Francisco, CA (Figure M7).  On day 1, the mice received 
intraperitoneal (IP) injections of 1x106 OVCA432-Luc cells and were subsequently 
divided into 2 groups of 10 each. The experimental group received 20 mg/Kg FP1039 
IP twice weekly while the control group received pooled human IgG at the same dose 
and schedule (Sigma Aldrich Corp, St Louis MO). Bioluminescence imaging was used  
 
Figure M7.  Structure and binding ability of  FP-1039 .FP-1039 is a soluble fusion protein consisting of the 
extracellular domains of human FGFR1 linked to the Fc region of human Immunoglobulin G1 (IgG1) FP-1039 is 
designed to bind multiple FGF ligands and prevent them from activating multiple FGF receptors. 
 
to follow tumor development in the mice on a biweekly basis. Imaging was performed 
on a the IVIS 100 imaging system with a data acquisition computer running Living 
Image software (Caliper Life Science , Hopkinton, MA).  Before imaging, animals were 
anesthetized with a 1.5% isoflurane/air mixture and followed by injecting IP. with 15 
mg/mL of D-luciferin firefly potassium salt (Caliper Life Sciences, Hopkinton, MA) in 
PBS at a dose of 150 mg/kg body weight.  A digital gray-scale animal image was 
acquired followed by acquisition and overlay of a pseudocolor image representing the 
  28 
 
spatial distribution of detected photon emerging from active luciferase within the 
animal. The animals were followed for a total of 8 wks after which the animals were 
sacrificed. Tumors were recovered, weighed, and processed for histological 
evaluation. 
 
Exon 9 -10 
Forward 5'-GCTGGGAGGGACTGAGTTAG-3’ 
Reverse 5’-TGGAGAAAGTCCAGCCTCAG-3’ 
Exon 11 
Forward 5'- CTACCTCTCGACCCACTATG-3’ 
Reverse 5’- GTCTTGCCATGTTGCCCAGG -3’ 
Exon 12 
Forward 5'- GATTCAGCCCTAGACCTACG-3’ 
Reverse 5’- CACTCCACGATCACGTAC -3’ 
Exon 13 
Forward 5'- CAACCTGCTTGGTGTCTG -3’ 
Reverse 5’- GGAAAGCGTGAATGCCTG -3’ 
Exon 14 
Forward 5'- TGGTGTGTGCTCAACTCCAG-3’ 
Reverse 5’- GTACACCCGGTCAAACAAGG -3’ 
Exon 15 
Forward 5'- CCAGCAACGTGAGGGAGATG-3’ 
Reverse 5’- CCAAATCTGAAGGAGCCCTCG -3’ 
Exon 16 
Forward 5’-TGTCCTACCCCACAAAAAGG-3’ 
Reverse 5’-AGGAGGACGAGGAGTTGTTG -3’ 
Table M2. Primer sequences for FGFR4 exons 9-16 
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Statistical Analysis  
SPSS version 17 (IBM Corporation Somers, NY) was used to perform all statistical 
test. Two-tailed Student’s t-test was used to test differences in sample means for data 
with normally distributed means. Mann-Whitney U test was used alternatively for non 
parametric data. Kaplan-Meier survival curves were generated and compared using a 
2-sided log-rank statistic. The Cox proportional hazards model was used for 
multivariate analysis. Pearson’s correlation coefficient was used to test linear 
associations. A p value < 0.05 was considered statistically significant.  
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Results 
FGF1 and FGFR4 DNA copy number are significantly amplified in HGSC  
Chromosome segment 5q31-35.3 was previously reported to be amplified and related 
to poor prognosis by our group in high grade serous ovarian carcinoma [10]. A 
correlation study between CGH and transcriptome profiling generated from 64 
independent microdissected HGLS ovarian tumor samples identified 17 genes that 
showed significant concurrence between DNA and mRNA copy numbers (Figure R1) 
in addition to FGF1 that we previously described. FGFR4 located in the same 
amplicon was found to show significant correlation between DNA and mRNA copy 
number, further study using qRT-PCR analysis also showed significant positive 
correlation between DNA copy number of FGF1 and FGFR4. (Figure R2). 
Figure R1. qRT-PCR validation of genes present on segment 5q31-35.3 from 51 microdissected tumor 
samples. Both FGF1 and the FGFR4 genes are significantly amplified and over-expressed in this area of the 
chromosome, which is linked to poor survival in high grade serous ovarian cancer patients [10].  
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The FGFR4 protein is overexpressed in HGSC and is related to poor survival  
Immunohistochemistry staining of FGFR4 in both normal ovarian surface epithelium 
and fallopian tube demonstrated lower expression compared to stained tumor (figure 
R3).  FGFR4 expression score was found to correlate negatively with survival(r=-0.49 
p<0.001, (Figure R4). The high FGFR4 Expression cohort demonstrated significantly 
decreased survival in Kaplan-Meier survival analysis were median survival was 24 
months compared with 55 months in the low expression cohort. Cox proportional 
hazard model after stratifying for age and debulking status also demonstrated 
increased risk of death with high FGFR4 expression (HR 2.1 p<0.01,Figure R5). 
The FGFR4 and FGF1 proteins are over expressed in vitro in HGSC 
Western blotting demonstrated a minimum 40 fold over expression of FGFR4 and 
FGF1 proteins in HGSC cell line lysates compared to human surface epithelial cells  
 
Figure R2.  DNA copy number of FGF1 and FGFR4 genes as determined by quantitative PCR from 51 micro 
dissected tumor samples.  Significant positive correlation is noted by person correlation (r=0.37, p<0.05,). 
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Figure R3. Overexpression of FGFR4 in high grade serous ovarian carcinoma. Expression of FGFR4 in high 
grade ovarian cancers (C1, C2) compared with ovarian surface epithelium (A) and fallopian tube epithelium (B) is 
demonstrated with overexpression being noted. 
 
 
Figure R4. Correlation of FGFR4 expression score with patient survival. 183 HGSC tumor sections were 
scored with a computer algorithm in arbitrary units for FGFR4 staining intensity (0=lowest – 255=highest). A 
significant negative correlation is noted.  
 
 
S u r v iv a l (M o n t h )
FG
FR
4 
Ex
pr
es
si
on
 S
co
re
0 50 10 0 15 0 2 00 2 50
0
5 0
1 00
1 50
r =  - 0 .4 9
p  =  < 0 .0 0 1
  33 
 
A 
Survival (Month)
P
er
ce
n
t 
su
rv
iv
al
0 50 100 150 200 250
0
20
40
60
80
100 Low FGFR4 Expression
High FGFR4 Expression
p<0.001
28 55
B 
 
Factor Hazard ratio 
(95%CI) 
p value 
optimal debulking 0.5(0.32-8.4) <0.01 
Age 1.0(0.9-1.1) N.S 
High FGFR4 
expression 
2.1(1.4-3.0) <0.01 
 
 
Figure R5. FGFR4 overexpression is associated with poor survival in advanced stage high grade serous 
ovarian carcinoma. (A) Kaplan-Meier survival function for 183 patients with HGSC divided into low and high 
FGFR4 expression based on a median expression score cut-off. High FGFR4 expressors median survival was 24 
months compared with 55 months in the low expression cohort.  Correlation with survival is maintained after 
stratification for age and debulking status. (B) Cox proportional hazard model indentified high FGFR4 expression as 
an independent risk factor for death in HGSC. 
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st in the OVCA432 cell line suggesting possible concurrent amplification of 5q 31-35.3.  FGF1 
was not detectable in conditioned medium by ELISA (Figure R7) in any of the cs tested. 
A 
B 
 
 
 
Figure R6. Expression of FGFR4/FGF1 in high grade ovarian cell lines.(A) Western blots demonstrating 
relative expression of FGF1/FGFR4 and β-actin in 6 HGSOC cell lines and human surface epithelial cells; (B) 
Protein expression normalized to actin from the immunoblots shown in (A).  
 
Cell Line 
A2780   SKOV3    OVCAR3   OVCA5  OVCA432  OVCA433 HOSE 
β A
ct
in
    
 F
GF
R4
    
 F
GF
1 
  35 
 
(Figure R6). Both FGFR4 and FGF1 expression were highest in the OVCA432 cell line 
suggesting possible concurrent amplification of 5q 31-35.3.  FGF1 was not detectable 
in conditioned medium (Figure R7) in any of the cell lines tested. 
Exogenous FGF1 treatment increased proliferation and survival in HGSC and activated 
multiple signaling pathways in vitro 
Exogenous FGF1 significantly increased proliferation by 11-54%  in 17 % of cell lines 
tested, survival was also increased by  a mean of 22% in 4 out 6 cell lines in vitro 
(Figure R8 and R9-A). Treatment with exogenous FGF1 significantly increased 
measured luminescence attributed to activation of the MAPK, WNT and NFkB 
pathways by 41-53% in the Cignal Lenti OVCA432 reporter assay, no significant 
change was noted in the remainder of the tested pathways (Figure R8). Activation of 
the pathways was verified by western blotting (Figure R13). Reverse phase protein 
array also indentified several proteins involved in cellular signaling that showed 
increased phosphorylation in response to FGF1 treatment including MAPK, PI3K and 
GSK3α. In addition, up regulation of BCL-xL and down regulation of E-cadherin was 
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Figure R7. FGF 1 in conditioned media from HGSC cell lines in vitro (A) Cells were plated on 100 mm plates 
until 70% confluent, serum containing medium was removed and Opti-MEM media was added, incubation for 48 
hours was then done, media collected, concentrated 50x and then subjected to FGF1 ELISA, none of the cells lines 
demonstrated any measurable FGF1 production in the media.      
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shown (Figure R12 & Table R1). In vitro transfection of FGFR4 targeted siRNA was 
successful in abrogating the effect of exogenous FGF1 in vitro both on cell behavior 
and cell signaling (Figure.R9-B and R11) FGF1 did not increase cellular migration in 
vitro in any cell line tested. Effects of selected FGF1 inhibitors and FGFR4 knock down 
are shown in Figure R14. With the exception FGFR4 knockdown, none of the FGF1 or 
FGFR inhibitors showed activity in vitro. However, FGFR4 trap protein was able to 
block the effects of exogenous FGF1 on OVCA432. 
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Figure R8. Effects of exogenous FGF1 on HGSC survival and proliferation in vitro. (A)Survival of HGSC cells 
incubated in serum free media for 72 hours with different concentration of FGF1 as measured by WST 1. Several 
cell lines demonstrate increased survival in a dose dependent fashion (B) Proliferation of HGSC cells, serum 
starved for 24 hours, and incubated for 24 h afterwards with varying concentrations of FGF1 with 2% FBS( all data 
points normalized to each cell lines control *=p<0.05, **=p<0.01, ***=p<0.001) 
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Figure R9. Proliferation of OVCA432 under different concentrations of FGF with and without transient 
FGFR4 knockdown (A) OVCA432 was plated in media containing 2% FBS for 24 hours on the XCELLigence array 
to allow attachment, data where normalized to the 24 hr time point after which the media was supplemented with 
FGF1 in different concentrations and the cells were followed for 84 hours using changes in electrical impendence to 
generate a cell index reflecting the number of cells present. FGF1 was noted to cause increased proliferation in a 
dose dependant manner(B) The experiment was then repeated with prior forward transient transfection with 
scramble siRNA in the 24 period prior to addition of FGF1 at 10 ng/ml and 2% FBS to the medium, scramble siRNA 
demonstrated significantly increased proliferation compared to the two FGFR4 Knockdown sequences   
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Figure R10. FGF1 effect on pathway activation in HGSC. Activation of signaling pathways in OVCA432 was 
screened by treating HGSC cell lines expressing transcription response elements linked to a luciferase reporter 
system with FGF1 and measuring subsequent light emission. MAPK , NFB and WNT pathway demonstrated 
significant increases in activity (* = p<0.05 , **=p<0.01,***=p<0.001) 
Figure R11. Transient FGFR4 knockdown reduced signaling activation triggered by FGF1. FGFR4 targeted 
siRNAs successfully inhibited increased pathway activation measured by luminescence in the luciferase reporter 
system previously described. 
  39 
 
  
Figure R12. Reversers phase protein array of OVCA432 treated at 
several time points. The array used 209 antibodies to probed for 
changes in expression levels of protein lysates After treatment with 
FGF1.Activation of MAPK , PI3K and WNT pathway is noted. BCL-xL is 
also up-regulated. E-Cadherin and cyclin B1 are down regulated.   
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Up regulated Proteins  Fold change  Down regulated Proteins  Fold change  
Phosphorylated MAPK(T202)  2.91  E. Cadherin  0.51  
Bcl-xL  1.83  Cyclin B1  0.44  
Phosphorylated GSK3α(S21)  1.54    
Phosphorylated PI3K (110a)  1.51    
Table R1. Up-regulated and down regulated proteins as shown by RPPA after treatment with FGF1 at 10 ng/ml for 
3 h  
Aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 
Figure R13.  Pathway activation in OVCA432 treated with FGF1.Western blots demonstrating change in 
phosphorylated protein levels in OVCA432 cells treated with FGF1 at 10 ng/ml for 1 hr (+) versus control (-).  
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Figure R14. Effect of different inhibitors of the FGF pathway on HGSC in vitro(A)HGSC cell lines were plated 
and serum starved for 24 hours and then media was removed with medium containing 2% FBS and one of 3 FGF 
pathway inhibitors and difference in proliferation measured via WST-1 assay, no significant difference is 
noted(B)HGSC cell lines were plated and serum starved for 24 hours and then media was removed with medium 
containing 2% FBS and 10 ng/ml FGF1 and the FGFR4 pathway was either knocked down transiently or blocked 
via FGFR4 trap protein, decrease in proliferation below normalization point is noted in the FGFR4 knock down arm 
and FGFR4 trap successfully inhibited the effect of exogenous FGF1 on OVCA432 cell line *=p<0.05, **=p<0.01, 
***=p<0.001)      
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FGFR4 knock down in vitro decreases cell survival, proliferation and migration  
Transfection with FGFR4 targeted siRNA resulted in significantly  decreased cell 
survival (in serum reduced media) by 31-65% (Figure R15) and decreased 
proliferation in media supplemented with 10% FBS by greater than 50% in all cell lines 
tested (Figure R16) . Migration of several cell lines was also decreased significantly 
from control (Figure R16). 
Figure R15. Effects of transient FGFR4 siRNA knockdown on HGSC Survival in vitro. Survival of HGSC cell 
lines after forward transfection with siRNA and incubation for 72 h in serum reduced media, significantly reduced 
survival was noted in cells transfected with FGFR4 targeted siRNA compared to those with scramble siRNA as 
measured by WST-1 assays,***=p<0.001.  
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Figure R16. Effects of transient FGFR4 siRNA knockdown on HGSC proliferation in vitro.  Proliferation of 
HGSC cell lines after forward transfection with siRNA at multiple time points over 72 hr period, inhibition of 
proliferation was demonstrated by both FGFR4 targeted siRNAs. 
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Figure R17. Effects of transient FGFR4 siRNA knockdown on HGSC migration in vitro. (A) Migration/invasion  
of HGSC cell lines into collagen matrix using ORIS assay system with and without the assay mask; (B) 
Quantization of migration/invasion into the central zone of ORIS assay via measurement of green fluorescence 
demonstrating a significant decrease in migration after FGFR4 knockdown(* = p<0.05 , **=p<0.01). 
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FGFR4 kinase and inter-membrane domains from clinical samples do not contain 
activating mutations 
6 patients out of 43 (14%) were positive for the Gly388Arg polymorphism in the 
intermembrane domain. Otherwise sequencing of exons 9 through 16 did not 
demonstrate any mutations in either the kinase or intermembrane domain.  
FGFR trap protein treatment reduced HGSC xenograft growth in vivo 
The FGFR1 trap protein was able to significantly reduce growth of xenografts 
OVCA432 in vivo as measured by serial luminescent imaging (Figure R18 & R19). 
H&E staining of xenografts revealed increased tumor necrosis and reduced tumor 
surrounding stroma (Figure 20)  
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Figure R18.   Quantitative Luminescent imaging of OVCA432 xenograft model treated with FP 1039. Two 
groups of mice, each injected IP with 1x106 cells of OVCA432luc, then were imaged at baseline 1 week after 
injection (week 0). Control group was injected 20 mg pooled human IgG twice weekly and FP 1039 group was 
injected with the FGFR1 trap protein at the same dose and schedule.  Significantly more luminescence is noted 
from the control tumor group p<0.05 
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Figure R 19. Tumor luminescence and distribution in OVCA432 treated with FP1039 versus control. 
Inhibition of tumor growth is noted in the FP1039 group versus control. 
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Figure 20. H&E sections from orthotopic xenograft tumors of OVCA432 in nude mice. (A)  tumors from a 
mouse treated with pooled human IgG (B) Tumor from a mouse treated with FP 1039 showing increased necrosis 
(N)and minimal stroma compared to placebo group(S) 
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Discussion and Conclusions 
Advanced stage high-grade serous carcinoma, as with many solid tumors, has 
undergone optimization of traditional therapeutic approaches over the last decade. 
Although this has led to improvements in survival and initial response to therapy, most 
patients with advanced stage disease still face poor prognosis, especially when in 
relapse or with metastatic disease[6, 7]. Characterization of genetic aberrations in 
these tumors and better understanding of molecular pathways involved in their 
pathogenesis/progression has fueled the development of targeted biologic agents for 
therapeutic intervention. When compared to traditional chemotherapy these agents 
posses a greater therapeutic index secondary to their relative selectivity for neoplastic 
cells[44]. In addition, biologic agents may have activity against those tumors that have 
become resistant to cytotoxic drugs. The heterogeneity of solid tumor genetic 
aberrations between patients has made it necessary to tailor such biologic therapy to 
the suitable molecular targets present within a tumor[79]. Our work demonstrates a 
possible target for such a personalized therapeutic approach in HGSC. 
Our previous report demonstrated the negative impact on survival in HGSC tumors 
harboring amplification of segment 5q31-35.3[10]. Although that segment contains 
hundreds of genes, it is notable for presence of several members of the FGF family.   
Evidence for the FGF pathway’s involvement in tumor development and progression is 
substantial. Prior reports have demonstrated the role of the FGF family in driving cell 
proliferation in solid tumors, including prostate and endometrial carcinomas[42, 80]. 
The proliferative effects appear to be mediated principally through the MAPK 
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pathway[27]. Successful inhibition of FGF pathway mediated cancer growth with 
biologic agents has been reported in vitro [54]. 
The mitogenic effects of FGF signaling may also be enhanced by activation of 
antiapoptotic pathways through the PI3K pathway. In small cell lung cancer FGF2 
overexpression is a known negative prognostic indicator. The decreased survival 
associated with FGF2 appears to be mediated by a cytoprotective effect involving 
upregulation of  the expression of the antiapoptotic proteins Bcl2, Bcl-xL through S6 
kinase[81].  
FGF signaling can also promote cell migration. Pancreatic cancer cells in vitro, have 
shown FGF10 and FGFR2 dependent invasion[82]. In a breast cancer mouse model 
activation of FGFR1 kinase domain led to invasive mammary lesions. In that model 
FGFR1 activation induced cell proliferation and survival, in addition to the gain of a 
matrix metalloproteinase 3, resulting in an invasive phenotype[83]. 
Our results demonstrate that activation of the FGF signaling axis through FGFR4 in 
HGSC leads to downstream activation of similar critical signaling pathways associated 
with phenotypic changes characteristic of more aggressive carcinomas.  
We have demonstrated the activation of MAPK pathway by FGF1/FGFR4 interaction 
and resulting proliferative effect. Overexpression of the FGF1 ligand and the FGFR4 
receptor in tumors with the 5q31-35.3 therefore may provide an autocrine signaling 
loop that drives tumor growth and proliferation in HGSC. Through the same loop the 
PI3K pathway may decrease apoptosis and increased survival of tumor cells. 
Additional FGF ligand involvement is likely as knock down of FGFR4 in absence of 
FGF1 and without known activating mutations leads to decreased cell proliferation and 
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cell death. This may be due to autocrine FGF18 overexpression, as it is also located 
on 5q311-35.3 amplicon, or other autocrine/paracrine FGF ligand production.  It is also 
evident that other pathways including WNT and NFkB are involved and their role is 
currently under investigation by our group. 
Our RPPA results also support that FGF1’s effect on cancer cells is mediated by 
activation of several signaling pathways. It also suggests that FGF1 signaling may play 
a more direct role in inhibiting apoptosis secondary to up regulation of Bcl-xL, and 
migration/invasion as evidenced by downregulation of E-Cadherin. This is consistent 
with previously published reports discussed earlier. However, the evidence we present 
is preliminary and requires further investigation. 
It also appears that different levels of FGFR4 amplification may have different effects 
on cell response in HGSC. The response to exogenous FGF1 by OVCA432, the 
highest expressor of FGFR4,  demonstrated increased proliferation and survival but no 
change in migratory behaviour Other cell lines with lower FGFR4 expression 
demonstrated significant increases in migration/invasion in addition to survival but no 
increase in proliferation.   
We did not observe in vitro production of FGF1 in conditioned media, although it was 
detected in cell lysate, and in tissue sections in our previous report [10]. This may be 
due to a short half life for the protein. It may also be that release in vivo requires 
certain conditions or co-signals that cannot be replicated by in monolayer cell culture 
environment.  
We have shown that in an orthotopic mouse model of HGSC use of the FP-1039 
FGFR1 trap protein significantly decreases tumor growth. FP-1039 is a fusion protein 
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of the extracellular domain of FGFR1 and IgG Fc fragment. The trap protein has broad 
spectrum binding activity to FGF ligands including FGF1 and is currently in phase 2 
trials in other gynecologic malignancies. The ability to sequester several FGF ligands 
and to inhibit the pathway upstream of the receptor allows FP-1039 to inhibit all the 
possible effects of overexpression of FGF ligands. This provides a therapeutic 
approach that interrupts autocrine signaling loops, hypothetically decreasing 
proliferation, survival and migration of tumor cells. Paracrine effects such as 
angiogenesis may also be inhibited.  
The challenge remains in identifying patients that may benefit from such an approach. 
This may be possible through identifying genetic and epigenetic changes particularly in 
genes involved in the FGF-FGFR axis that are associated with the responsiveness of 
the FGFR trap in preclinical mouse models. 
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